Wormin

Quick links to important sections

Wormin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wormin

Property Description
Active ingredient Mebendazole
Form Oral tablet, Chewable tablet, Oral suspension
Pharmacological class Anthelmintic, Anti-infective
Common use Clearance of intestinal helminthic infections
Origin Synthetic benzimidazole derivative

Wormin is a specific brand name for a prescription-only medication whose active pharmaceutical ingredient is Mebendazole (MBDZ), classified as a broad-spectrum anthelmintic. This medication belongs to the anti-infective category, specifically designed to eliminate parasitic worms. The drug’s purpose is to manage and resolve infections caused by various helminths found in the human intestine.

What Type of Medicine is Wormin (Mebendazole)?

Wormin is a synthetic medication that falls into the chemical group of benzimidazole derivatives, meaning it is a compound that has been intentionally synthesized for therapeutic use. Its effectiveness is clinically recognized for addressing infections across a wide geographical distribution. The identity of the active compound, Mebendazole, is defined by the core chemical formula, C16H13N3O3, and it functions as an antinematodal agent effective against parasitic species such as pinworms and whipworms. Mebendazole is used for the treatment of single or mixed-species helminth infections, reflecting the drug's established utility in helping to clear the body of intestinal worm infestations.

Composition, Forms, and General Therapeutic Purpose

The medicine is a single-ingredient product, consisting solely of the active compound Mebendazole combined with necessary inert excipients to create the final dosage form. The availability of Wormin as both a standard oral tablet and a chewable tablet provides a feature that differentiates it from single-form preparations, offering a choice that can be beneficial for different patient populations. The general therapeutic purpose of this medicine is deworming the host, achieving the clearance of various intestinal helminthic infections. For instance, it is typically used in cases where a household member has been diagnosed with pinworms, making it necessary to address potential spreading of the infection.

What side effects are possible with Wormin?

The safety profile of Wormin (Mebendazole) is categorized by frequency and system-organ class according to official regulatory documentation. This structure helps classify reported adverse events.

Documented Adverse Reactions

Side effects are classified into frequency tiers based on reporting rates:

Frequency Examples (Organ System)
Common Headache (Nervous System), Abdominal pain, Diarrhea (Gastrointestinal)
Uncommon Flatulence (Gastrointestinal), Rash, Hypersensitivity reactions (Skin/Immune)
Rare Dizziness (Nervous System), Reversible Alopecia (Skin and Subcutaneous Tissue)

The most frequently reported events primarily affect the Gastrointestinal System (abdominal pain, diarrhea) and the Nervous System (headache). Rare, but serious, adverse reactions documented in official labeling include blood disorders such as agranulocytosis and neutropenia, as well as severe skin reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Reports of hepatitis and abnormal liver function tests are also noted in the safety literature.

Safety Constraints and Special Populations

The regulatory profile specifies safety considerations for certain patient groups and contexts. Use of Mebendazole in children under 2 years of age has been associated with reports of convulsions. Additionally, individuals with severe hepatic impairment may experience increased plasma concentrations of the medicine. The label documents a safety constraint regarding the concurrent administration of Mebendazole with Metronidazole, noting an association with severe dermatological reactions (SJS/TEN) when used together. Furthermore, the risk of serious blood disorders is documented as being increased with prolonged use or high doses.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for Wormin (Mebendazole) overdose is defined by specific signs, potential severe complications, and regulator-mandated emergency actions.


Documented Manifestations and Severe Outcomes

Overdose Presentation Regulatory Documentation Summary
Common Signs The most commonly reported signs of over-ingestion are transient gastrointestinal disturbances, including abdominal cramps, nausea, vomiting, and diarrhea.
Severe Outcomes Adverse findings associated with exposure to dosages substantially higher than recommended or for prolonged periods include reversible liver function disturbances, hepatitis, and hematologic effects such as agranulocytosis and neutropenia.
Population Notes Convulsions have been reported very rarely following over-ingestion, including in infants below the age of one year.

Required Emergency Actions

Management of Mebendazole overexposure is primarily symptomatic and supportive. The regulatory labeling explicitly states that no specific antidote is known for this compound. The administration of activated charcoal may be considered appropriate in certain cases.

Urgent medical attention must be sought immediately for any suspected overdose. Emergency services must be contacted at once if the individual experiences severe symptoms such as collapse, seizure, trouble breathing, or cannot be awakened. These actions are required to address the potential for rare, serious systemic toxicities documented by health authorities.

Therapeutic Uses of Wormin

What Wormin Treats: Main Uses and Benefits

Wormin (Mebendazole) is commonly used for managing symptomatic distress associated with intestinal helminthic infections. It is relevant for symptoms linked to parasitic species such as pinworm (Enterobiasis), roundworm (Ascariasis), whipworm (Trichuriasis), and hookworm. Mebendazole is an anthelmintic applied to address these types of infections. It supports the management of the infestation, which may assist in easing the overall symptom load associated with the infectious process.


This medication helps manage symptom clusters that may become intense or disruptive, including gastrointestinal discomfort and recurring intestinal pain. It supports the easing of symptoms related to severe perianal itching, particularly when manifestations interfere with daily comfort, and contributes to improved comfort during periods of heightened symptoms. The medicine is relevant for patients in contexts involving parasitic infection within a community or family setting, where symptoms may affect multiple individuals. Its use in high-risk groups, including school-aged children, provides supportive relief when symptoms interfere with routine activities.

“This medicine is relevant in contexts involving irritative processes and is applied across domains where additional symptomatic support is needed.”

Quick Fact: Used for managing symptoms related to Intestinal Discomfort and Nocturnal Itching

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility profile for Wormin (Mebendazole) is strictly defined by regulatory documents, establishing clear patient groups who can and cannot use the medicine.

Contraindicated Populations

Use is strictly contraindicated in persons with known hypersensitivity to Mebendazole or its excipients. The medicine is also contraindicated for children below the age of one year due to reports of convulsions and a lack of sufficient safety data in this age group.

Age and Conditional Eligibility

Age Group Regulatory Status
Children 2+ years Permitted (Standard Labeled Use)
Children 1-2 years Not Extensively Studied (Use Conditional)
Geriatric (65+) Use Not Established (Insufficient Data)

Mebendazole is generally permitted for use in adults and children two years of age and older. A significant restriction is the instruction to avoid the concomitant use of Mebendazole with metronidazole.

Physiological Restrictions

Use is recommended with caution in patients with hepatic impairment due to the potential for increased drug exposure. Additionally, caution should be exercised for nursing mothers, and use during pregnancy is typically not recommended.

What should I know about interactions with other medicines?

Contraindicated Combinations and Pharmacodynamic Risk

Concomitant use of Mebendazole (the active ingredient in Wormin) and Metronidazole is officially documented in regulatory sources and should be avoided. This restriction is due to post-marketing reports of an increased risk of serious adverse skin reactions, specifically Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pharmacokinetic and Exposure-Altering Interactions

Certain medicinal products have been documented to alter the plasma concentrations (exposure) of Mebendazole:

  • Cimetidine: Co-treatment may inhibit Mebendazole metabolism, resulting in an increase in Mebendazole plasma concentrations.
  • Phenytoin and Carbamazepine (Anticonvulsants): Co-treatment may reduce the plasma levels of Mebendazole, which could potentially decrease its systemic exposure.

Food and Population-Specific Interactions

  • Food Interaction: Mebendazole absorption is officially noted to be increased by fatty food intake, affecting its overall systemic exposure.
  • Hepatic Impairment: Patients with impaired liver function may exhibit higher systemic plasma concentrations of Mebendazole, which may affect the severity of other metabolic interactions. No mandatory time separation rules are documented in the official regulatory labels.

Connection to the Overall Interaction Profile

Regulatory documentation establishes a primary restriction against the co-administration of Metronidazole due to a documented severe pharmacodynamic risk. The remaining interaction profile is defined by pharmacokinetic interactions where enzyme-modifying agents alter Mebendazole exposure by either increasing or decreasing its plasma levels. This framework also accounts for fatty food and impaired hepatic function as documented conditions that modify the drug's systemic concentration.

Mechanism of Action

Mebendazole operates by highly selective binding to the beta-tubulin subunit protein found in the parasitic worm's cells. This binding acts as an inhibitor that prevents the alpha and beta tubulin components from assembling into functional microtubules. The mechanism is characterized by a high affinity for helminth beta-tubulin, resulting in its localized physiological impact on the parasite and leading to the disintegration of the worm's intestinal cells. This structural damage directly blocks the parasite's ability to absorb glucose, its primary source of energy. This action initiates a metabolic cascade leading to rapid depletion of glycogen stores and the severe impairment of ATP synthesis. The resulting profound energy deficit leads to parasite immobilization and death, resulting in the organism's elimination from the body. The mechanism's effectiveness is highly dependent on the parasite's developmental stage; its ovicidal activity (action against helminthic eggs) is often less potent and more variable, contributing to the gradual nature of the drug's overall physiological effect.

Dosage and Administration Information

Official Administration Guidelines for Wormin (Mebendazole)

The use of Wormin is restricted to the oral route of administration, regardless of the formulation (tablet, chewable tablet, or suspension). Official instructions for use are defined by the specific parasitic infection being addressed, establishing distinct short-term dosing regimens.

Feature Official Use Instruction
Dosing Schedule Pinworm (Enterobiasis): A single oral dose of 100 mg or 500 mg is administered. Other Infections: 100 mg is taken twice daily for 3 consecutive days.
Timing in Relation to Meals The medicine may be administered with or without food. Fasting, dietary modifications, or purging are not required.
Preparation Requirements The 100 mg tablet can be chewed, swallowed whole, or crushed and mixed with food. The 500 mg chewable tablet must be chewed completely and must not be swallowed whole.
Age-Group Rules Dosing generally follows the standard schedule for children above the minimum age established by the label (often 2 years or older); use in children under 2 years is subject to specific constraints.
Procedural Condition If required due to the persistence of the infection, a second full course of treatment is advised to be taken 2 to 4 weeks after the initial course.

Resulting Procedural Structure

The official use protocol is structured as a short-term, intensive course. Treatment begins by determining the appropriate single-day or 3-day frequency pattern. The patient ingests the medicine orally, with the requirement to properly chew specific tablet forms to ensure correct administration. The overall protocol includes a defined re-treatment cycle to address the management of potential re-infection or persistent parasitic presence, as outlined in official documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Wormin (Mebendazole)

The research available for Mebendazole (the active ingredient in Wormin) focuses on its evaluation as an anthelmintic for various intestinal parasitic infections. This overview describes the research landscape according to official and peer-reviewed scientific sources, including the types of studies conducted and what the findings generally indicate about measured outcomes, without offering any clinical guidance.


Evidence for Use in Roundworm (Ascariasis) and Pinworm (Enterobiasis)

The evidence exploring the evaluation of Mebendazole for roundworm and pinworm relies heavily on Randomized Controlled Trials (RCTs) and is summarized in extensive systematic reviews. Researchers have primarily monitored outcomes related to parasite status, specifically measuring the Parasitological Cure Rate and the Egg Reduction Rate. These studies focused on populations of school-aged children and adults.

Research conducted during these observed time intervals has consistently described patterns of reported measurements related to clearance across the populations examined for these specific infections. For instance, studies reported measurements of a pronounced reduction in the number of eggs counted in stool samples for roundworm. However, the available follow-up durations were typically limited to a few weeks or months, meaning long-term effects and the persistence of the observed change are not fully established.


Evidence for Use in Whipworm (Trichuriasis) and Hookworm

Research examining Mebendazole's evaluation for whipworm and hookworm involves RCTs and comparative efficacy studies exploring different treatment schedules. For hookworm, studies found that reported measurements consistently show pronounced Egg Reduction Rates. However, when focusing on the stringent outcome of the Parasitological Cure Rate, findings indicated that the measurements were frequently low, particularly when only a single dose was examined.

For whipworm, studies also reported that the Parasitological Cure Rate measurements were generally lower than those described for roundworm. The most frequently evaluated treatment schedules for measured outcomes in whipworm remain an area of ongoing research, as findings were mixed across single-dose versus multi-dose interventions.


What is Still Uncertain About the Research for Mebendazole

While studied across numerous investigations for certain infections, the research still contains areas where certainty remains low or evidence is limited. Data remains insufficient for very young children (e.g., under two years of age) or older adults, and subgroup findings for individuals with significant pre-existing health conditions are uncertain. Additionally, comparative evidence is lacking for some newer treatment approaches, and research provides context about group patterns but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Mebendazole: MedlinePlus Drug Information (Used for general indications and special population context)

Frequently Asked Questions (FAQ)

Common questions about Wormin (FAQ)


Q: How quickly does Wormin start working after taking it?

A: Regulatory documents indicate that the active compound, mebendazole, is eliminated from the body within a matter of hours, with a typical half-life between 2.5 and 5.5 hours. The medicine works by gradually preventing the worm from absorbing nutrients. This action suggests that the full therapeutic effect is typically gradual, rather than immediate.


Q: Does the efficacy of Wormin depend on what I eat before taking it?

A: Official information states that this medicine can be taken with or without food, and specific diets are not required. It is documented, however, that taking the drug with a fatty meal can increase the amount of the active compound absorbed into the bloodstream. However, official information does not define whether this change in absorption guarantees an altered treatment outcome.


Q: Is it necessary for all family members to be treated with Wormin at the same time?

A: For certain types of infections, such as pinworm, re-infection is known to be very common. Official guidance often describes the protocol of treating household members concurrently for infections like pinworm, given the high risk of re-infection or transmission within the home.


Q: Are there generic versions of Wormin available?

A: Wormin is a brand name for the active ingredient, mebendazole. This compound is available under its generic name and is manufactured by various companies worldwide. Regulatory bodies, such as the FDA, list several products containing mebendazole that are approved for use.


Q: What happens if I miss a dose of Wormin?

A: Regulatory patient directions often outline a protocol where a missed dose is taken as soon as it is remembered. However, if the timing is close to the next dose, the protocol usually suggests skipping the missed dose. The established protocol generally recommends against taking a double dose to compensate for a missed one.


Q: Can Wormin cause changes in my stool or urine color?

A: The most commonly reported side effects affect the digestive system, such as abdominal pain. Official documentation notes that rare adverse events have included the reporting of dark urine or light-colored stools. These less common effects are documented in official safety literature as having a potential association with liver function.


Q: Are there any common foods or drinks to avoid while using Wormin?

A: The official labels generally do not mandate special dietary restrictions or fasting. The medicine can be taken with or without food. However, some regulatory documents note that the combination of this medicine and alcohol is not thoroughly established. Therefore, caution related to alcohol use during the treatment period may be noted.


Q: How long does Wormin stay in the body?

A: The active compound is eliminated relatively quickly. In individuals with normal liver function, official pharmacokinetic data indicates an elimination half-life typically ranging from 2.5 to 5.5 hours. The elimination process is noted to take longer in patients who have impaired liver function.


Q: Can children of all ages use Wormin?

A: Regulatory labels state that use is permitted for adults and children two years of age and older. The medicine is contraindicated (advised against) for children under one year old due to documented reports of convulsions in this age group. Use in children between one and two years old is not routinely labeled and is conditional, depending on an individual benefit/risk assessment.


Q: Does taking Wormin mean I will definitely see worms in my stool?

A: Wormin works by causing the death of the parasitic worms, which are then eliminated from the body. While larger parasites, such as roundworms, might be visible in the stool during the process of clearance, the elimination of very small worms, like pinworms, may not be physically noticeable.


Q: Is a follow-up dose of Wormin usually needed?

A: For pinworm infections, re-treatment is often recommended to manage the high risk of re-infection. Official protocols advise that a second full course may be taken 2 to 4 weeks after the initial dose if the infection is found to persist or if re-infection occurs.


Q: If I have a known kidney condition, can I still take Wormin?

A: The official information for use in renal (kidney) impairment generally suggests that dose adjustments are not recommended for individuals with kidney conditions, including those undergoing dialysis. This is because the drug is primarily processed and metabolized by the liver, not the kidneys.


Q: Are there specific times of day that Wormin is usually recommended to be taken?

A: The specific dose is often prescribed to be taken consistently, such as twice a day for a three-day course. The official administration guidelines indicate that the timing is flexible, and the medicine can generally be taken at any time of day, with or without food.


Q: Does Wormin only kill adult worms, or does it affect eggs/larvae too?

A: The drug's primary action targets the larval and adult stages of susceptible parasites. Regulatory information notes that the drug's activity against the eggs (ovicidal activity) is generally considered less potent and more variable. This is a factor in the recommendation for potential re-treatment cycles.


Q: Why do some people experience nausea or stomach upset with Wormin?

A: Official drug documentation notes that common side effects include gastrointestinal issues, such as abdominal pain and diarrhea. Official documentation notes that these symptoms may be associated with the process of the parasite being eliminated from the body, particularly in cases where a high parasitic burden is present.


Q: Can I take Wormin if I have a known allergy to similar drugs?

A: The medicine is strictly contraindicated (advised against) in persons with a known hypersensitivity to the drug, mebendazole, or its specific excipients (other ingredients). Official documents focus on allergy to the active ingredient itself rather than general allergy to other drug classes.


Q: Why is Wormin sometimes prescribed in a single-day treatment course?

A: The treatment schedule is determined by the specific parasitic infection being addressed. A short, single-day course is generally prescribed for infections like pinworm, while other types of parasitic infections require a multi-day course. This difference is based on the specific lifecycle and characteristics of the targeted parasite.


Q: Is there a maximum number of times a person can take Wormin in a year?

A: The official dosing protocol includes the option for a re-treatment cycle 2 to 4 weeks after the initial dose if reinfection occurs. Regulatory documents do not set an explicit yearly maximum, but they do caution that prolonged use or higher doses are associated with an increased risk of serious adverse reactions.


Q: Does Wormin cause a metallic taste or dry mouth?

A: The most frequently reported adverse events are common gastrointestinal effects like abdominal pain and diarrhea. Official regulatory documentation does not typically list a metallic taste or dry mouth among the commonly, uncommonly, or rarely reported adverse events.


Q: Are there any specific lifestyle restrictions while taking Wormin?

A: Official patient information highlights the importance of good hygiene practices, such as frequent handwashing and laundering of clothes and bedding, as these actions help manage the risk of re-infection and transmission.


Q: How is the safety of Wormin monitored after it is released to the public?

A: The safety of this medicine is monitored through a process called postmarketing surveillance. Regulatory bodies collect and analyze adverse reactions and side effects reported by patients and healthcare professionals after the product has been released. This helps identify and document rare or serious effects over time.


Q: What kind of parasites is Wormin not effective against?

A: Official regulatory indications explicitly state which intestinal parasites the medicine is effective against, such as pinworm, roundworm, and whipworm. It is important to note that it is not generally indicated for treating infections caused by protozoa (single-celled organisms) or flukes, which require a different class of medication.

How should Wormin be stored and disposed of?

How to Store and Dispose of Wormin (Mebendazole)

The storage and disposal of Wormin tablets must comply strictly with regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

Wormin must be stored at Controlled Room Temperature, which is defined as between 20 C to 25 C (68 F to 77 F). The official guidelines permit brief temperature excursions between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original container.

Child Safety Mandate

It is a mandatory safety instruction that this and all medications must be kept out of the reach of children.

Disposal Instructions

Unused or expired Wormin must be safely discarded. Regulators recommend using a drug take-back location or a mail-back program as the preferred disposal method. If these are unavailable, the medicine may be disposed of in household trash by mixing it with an unpalatable substance (such as used coffee grounds or dirt), placing the mixture into a sealed container, and then discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wormin found in:

A-Z Index: